Humira(Cf)(Adalimumab)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$400.9M
Medicare cost, 2024
$400.9M
Medicare cost, 2024
Medicare drug plans spent $400.9 million on Humira(Cf) (adalimumab) in 2024, for 46,620 prescriptions and refills filled by 6,661 patients. At about $8,599 per prescription it is a high-cost drug. Texas accounts for the most spending ($31.8 million, 8% of the total).
Medicare cost, 2024
$400.9M
-10.1% from 2023
Prescriptions
47K
$8,599.32 per claim
Patients
6,661
5,384 prescribers
Total spending, 2024
$400.9M
$60,186.23 per patient
Questions and answers
How much does Medicare spend on Humira(Cf)?
Medicare prescription drug plans paid $400.9M for Humira(Cf) in 2024, for 46,620 prescriptions and refills to 6,661 patients (down 10.1% from 2023). The average cost per claim was $8,599.32.
Which state spends the most on Humira(Cf)?
Texas had the highest Medicare cost for Humira(Cf) in 2024: $31.8M for 3,552 claims, followed by New York ($30.9M).
Who prescribes Humira(Cf) the most?
Michael Babilonia Roman, internal medicine in Mayaguez, PR, had the highest Medicare cost for Humira(Cf) in 2024: 265 claims costing $1.8M.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Humira(Cf) was $400.9M in 2024, after a high of $445.8M in 2023.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Humira(Cf), 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Michael Babilonia Roman Mayaguez, PR | Internal Medicine | 265 | 28 | $1.8M |
| Elvin R Garcia McAllen, TX | Rheumatology | 194 | 25 | $1.4M |
| Roger R Wang San Francisco, CA | Allergy/ Immunology | 212 | 25 | $1.3M |
| Ya Ju Chang New York, NY | Rheumatology | 176 | 20 | $1.2M |
| Carl Restivo Jr. Jersey City, NJ | Rheumatology | 149 | 15 | $1.1M |
| Roberto D Alvarez Aibonito, PR | Rheumatology | 148 | 20 | $1.0M |
| Ravi Bhalla Peoria, AZ | Rheumatology | 93 | 12 | $895K |
| Jonathan Rene Saginaw, MI | Rheumatology | 79 | Under 11 | $707K |
| Allan A Ramey Lancaster, MA | Rheumatology | 89 | Under 11 | $671K |
| Bradley Toews Tulsa, OK | Physician Assistant | 68 | Under 11 | $664K |
| Thomas E Lafferty Ocala, FL | Rheumatology | 69 | Under 11 | $657K |
| Yong H Tsai Daytona Beach, FL | Rheumatology | 89 | 11 | $656K |
| Osvaldo Antommattei Ponce, PR | Rheumatology | 97 | 11 | $650K |
| Anthony M Kahr Bend, OR | Rheumatology | 89 | Under 11 | $624K |
| Preethi Thomas Radnor, PA | Rheumatology | 50 | Under 11 | $621K |
| Grace A Makhlouf Sugar Land, TX | Rheumatology | 36 | Under 11 | $617K |
| Monika Mohan Okemos, MI | Rheumatology | 80 | 11 | $566K |
| Shirley A Albano Hershey, PA | Rheumatology | 68 | Under 11 | $534K |
| James E Dowd Brighton, MI | Rheumatology | 68 | Under 11 | $521K |
| Roy C Sampson Lowell, AR | Rheumatology | 74 | Under 11 | $503K |
| Stephannie L Legarretta Horizon City, TX | Nurse Practitioner | 54 | Under 11 | $490K |
| Susan M Goodman New York, NY | Rheumatology | 61 | Under 11 | $488K |
| Kenneth B Wiesner Sacramento, CA | Rheumatology | 44 | Under 11 | $485K |
| Marta T Bognar Gainesville, GA | Rheumatology | 67 | Under 11 | $484K |
| Zaida Z Fuxench Lopez Bayamon, PR | Internal Medicine | 33 | Under 11 | $456K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 5,415 | 49,564 | 7,125 | $410.2M |
| 2023 | 5,551 | 49,822 | 7,028 | $445.7M |
| 2024 | 5,384 | 46,620 | 6,661 | $400.9M |
Makers, 2024
Spending by manufacturer as listed in the spending data
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 716,864 side-effect reports named adalimumab, the active ingredient of Humira(Cf) (reports from 1993 on). 367,566 of them (51.3%) were serious, 31,605 named a death and 152,383 named a hospital stay. The reactions named most often were drug ineffective, pain and arthralgia. 187,721 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
716,864
23,258 in 2025 (-20.8% from 2024)
Serious
51.3%
367,566 reports
Deaths named
31,605
4.4% of reports
Hospital stays
152,383
21.3% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
Since 2002. 2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Humira(Cf)?
716,864 reports from 1993 through September 2026 named adalimumab, the active ingredient of Humira(Cf). 367,566 of them (51.3%) were serious, 31,605 named a death and 152,383 named a hospital stay.
What are the most reported side effects of Humira(Cf)?
92,932 reports named drug ineffective, the reaction named most often, followed by pain (50,798) and arthralgia (49,681). In the last 5 years the reaction named most often was drug ineffective (22,775 reports). A report can name several reactions.
How many side-effect reports named Humira(Cf) in 2025?
23,258 reports were received in 2025 (-20.8% from 2024). 2026 so far: 12,817 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Humira(Cf) caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Humira(Cf) caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with adalimumab: Humira(Cf) Pen, Humira Pen, Humira, Humira(Cf) Pen Crohn's-Uc-Hs, Humira(Cf) Pen Psor-Uv-Adol Hs, Humira Pen Crohn's-Uc-Hs, Humira Pen Psor-Uveits-Adol Hs, Humira(Cf) Pediatric Crohn's
- Makers on the stock market:
ABBV·ABBV drug pipeline - Drug approvals (1 approval on file for adalimumab) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (adalimumab) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.